Research and Consulting Services(IN40252.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Research and Consulting Services
IN40252.SH
News
View More

Fourier: Brain-machine interfaces will be introduced into robotic rehabilitation training in the next 1-2 years

Gu Jie, the founder and CEO of Fourier, stated at the Second Fourier Embodied Intelligence Ecological Conference that in the next 1-2 years, brain-computer interface technology will be introduced into robotic rehabilitation training to assist patients in completing movements by providing support through brain-computer intention recognition, achieving a complete closed-loop training

Wallstreetcn·
SZ
003008
+0.82%
SZ
300486
+1.92%
Wallstreetcn·
SZ
003008
+0.82%
SZ
300486
+1.92%

Zhejiang Merchants Property Insurance's net profit surged 2.6 times: underwriting ability turns profitable, premium scale under pressure

Zhejiang Commercial Property Insurance achieved a net profit of 151 million yuan in 2025, a year-on-year increase of 266.6%. The company improved its underwriting capabilities, reducing the comprehensive cost ratio to 99.66%, successfully turning losses into profits. Although insurance business revenue slightly declined to 3.791 billion yuan, the management chose to optimize the business structure to enhance profits. Meanwhile, the investment return rate also improved, with the comprehensive investment return rate rising from 4.47% to 5.18%. By the end of 2025, the company's solvency adequacy ratio significantly rebounded to 215.29%. In addition, Jiang Zhaohui has been appointed as the company's chairman and party secretary

Wallstreetcn·
SZ
003008
+0.82%
Wallstreetcn·
SZ
003008
+0.82%

03:18 ET Libevitug Approved in China as First-in-Class Treatment for Hepatitis D

Huahui Health's Libevitug injection has received conditional approval from China's NMPA as the first treatment for chronic hepatitis D. This human monoclonal antibody targets the PreS1 domain of HBV and HDV, blocking viral entry into liver cells. Libevitug addresses a significant clinical gap, especially in China, where over 75 million people suffer from chronic hepatitis B. The drug showed superior efficacy in clinical trials, with a combined response rate of 44.1% and a virological response rate of 60%. It aligns with China's goals to improve hepatitis diagnosis and treatment by 2030.

prnewswire·
US
XBI
-2.02%
US
BBH
-1.27%
US
SBIO
-2.09%
prnewswire·
US
XBI
-2.02%
US
BBH
-1.27%
US
SBIO
-2.09%

00:56 ET Moyom Biotechnology Announces Strategic Partnership with WPP Group to Elevate Aphranel's "Poetics of Time" Brand Positioning

Moyom Biotechnology has announced a strategic partnership with WPP Group to enhance the global brand positioning of Aphranel's "Poetics of Time" framework. This collaboration aims to establish a consistent and internationally relevant brand narrative, emphasizing the scientific and clinical values behind Aphranel, the first CaHA-based regenerative injectable approved in China. WPP will leverage its global resources to expand Aphranel's reach and build long-term brand trust across markets, focusing on a philosophy that respects anatomy and long-term clinical value in aesthetic medicine.

prnewswire·
US
NNNN
-10.32%
US
IHI
-0.63%
US
SANA
-4.43%
prnewswire·
US
NNNN
-10.32%
US
IHI
-0.63%
US
SANA
-4.43%

The CSRC temporarily revoked Huang Zhihui's license for 27 months

The China Securities Regulatory Commission announced the temporary suspension of the license of Huang Zhihui, a former licensed representative of FuChang Securities and FuChang Futures, for a period of 27 months. This is due to his involvement in approximately 1,300 personal transactions amounting to 670 million yuan from 2019 to 2022, conducted without the company's knowledge, by opening accounts in the name of relatives at another brokerage. Additionally, from 2015 to 2018, Huang Zhihui conducted approximately 10,000 transactions totaling 2.8 billion yuan through accounts opened in the name of relatives at Kaipan Securities without the company's approval. His actions are considered a deliberate circumvention of regulations, affecting the company's monitoring mechanisms and raising questions about his licensing suitability

AASTOCKS·
SH
512880
-0.75%
SZ
159842
-0.70%
SZ
003008
+0.82%
AASTOCKS·
SH
512880
-0.75%
SZ
159842
-0.70%
SZ
003008
+0.82%
© 2026 Longbridge｜Disclaimer